Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and DDI of EYP651 (Vonafexor Lysine Salt) in Healthy Volunteers
NCT07251153Phase 1Recruiting
- Sponsor
- ENYO Pharma
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EYP-651 in metabolic dysfunction-associated steatohepatitis (MASH) and Alport syndrome, sponsored by ENYO Pharma. Primary endpoints: Pharmacokinetic Area Under the Curve at 1 day, Pharmacokinetic Maximum Plasma Concentration at 1 day and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
EYP-651
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Alport syndrome
Beyond the preview
Go deeper on NCT07251153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251153.